{"prompt": "['considered medically necessary, the Medical Monitor should be consulted to discuss any changes', 'in the benefit-risk profile and determine whether the patient should continue on the study.', 'Any over-the-counter medication used to treat the symptoms of hemophilia', 'Supplementary vitamins and minerals.', 'Drugs and therapies to treat adverse events and the use of topical antiseptics, anesthetics, eye', 'drops, etc., that are not considered to enter the bloodstream and result in systemic exposure', 'Concomitant use of the following hemostatic treatments will be permitted:', 'Drugs intended to control breakthrough bleeds (e.g. rFVII, FVIII, aPCC) or bleeds during', 'surgeries should be used at the lowest dose expected to achieve hemostasis. Given that circulating', \"emicizumab may increase the patient's coagulation potential, the doses required to achieve\", 'hemostasis may be lower than doses used prior to starting emicizumab. At the start of the study,', 'Investigators shall discuss with patients the recommended doses of any additional coagulation', 'factors used, given the guidance below.', 'The use of aPCC for breakthrough bleed treatment for patients on emicizumab should be avoided', 'if possible, and rFVIIa should be the first option used to treat, starting with no more than 90', 'g/kg as an initial dose. If aPCC needs to be used, no more than 50 IU/Kg should be administered', 'as an initial dose and doses of > 100 U/kg/24 hours or more should be avoided, as cases of TMA', 'and thrombotic events were reported when on average a cumulative amount of > 100 U/kg/24', 'hours aPCC was administered for 24 hours or more. Investigators should provide or remind', 'patients of the exact dose and schedule of bypassing agents or FVIII required to treat any bleed.', 'Caution should be taken if anti-fibrinolytics are used in conjunction with rFVIIa in patients', 'receiving emicizumab', 'Other bypassing agents: other bypassing agents (e.g., Byclot\u00ae) should be avoided. In', 'cases where such agents are the only available bypassing agent, the lowest dose', 'expected to achieve hemostasis should be prescribed, with no more than the lowest', 'dose described in the prescribing information to be administered as an initial dose (e.g.,', 'no more than 60 mg/kg of Byclot\u00ae). For patients receiving Byclot\u00ae prior to study entry, a', 'washout period of 72 hours prior to the first emicizumab dose is required', 'The exact dose and schedule of FVIII or bypassing agents should', 'be discussed with the patient at study entry and throughout the', 'study. Repeated dosing of FVIII, rFVIla, aPCC, or other bypassing', 'agents should be performed only under medical supervision and', 'consideration should be given to verifying the bleeds prior to', 'repeated dosing. For rFVIla, aPCC, and other bypassing agents,', 'laboratory monitoring by additional local and central laboratory', 'assessments should be performed as per the Schedule of Activities', '(see Section 4.5.6.9Appendix', '1', 'Schedule of Activities', ').', 'Emicizumab - F. Hoffmann-La Roche Ltd', '115 / Protocol MO39129, Version 3']['4.4.2', 'Prohibited Therapy', 'Use of the following therapies is prohibited during the study:', 'Use of systemic immunomodulators (e.g., rituximab, interferon) other than antiretroviral', 'therapy', 'Use of other investigational drugs', 'Use of aPCC for short-term prophylaxis', 'Use of aPCC for any reason should be avoided if possible during the study but use of', 'aPCC to treat breakthrough bleeds is permitted (as described in Section 4.4.1) if', 'rFVIla is not available or not an option for medical reasons (see Section 0).', 'Use of ITI therapy (prophylactic regimens with FVIII and/or bypassing agents):', 'However, short-term prophylaxis around the time of surgery is permitted as deemed', 'needed by the investigator (see Section 4.4.1). FEIBA can not be used prophylactically.', 'Use of anti-fibrinolytics in conjunction with aPCC or Byclot\u00ae', 'If prohibited therapy is administered for any reason, it should be recorded on the eCRF. If', 'prohibited treatment is prescribed or considered medically necessary, the Medical Monitor', 'should be consulted to discuss any changes in the benefit-risk profile and determine whether', 'the patient should continue on the study.', '4.5', 'STUDY ASSESSMENTS', 'Please see Appendix 1', 'Schedule of Activities', 'for the Schedule of Activities to be performed during the study.', '4.5.1', 'Informed Consent Forms and Screening Log', 'Written informed consent for participation in the study must be obtained before performing', 'any study-specific screening tests or evaluations. Informed Consent Forms for enrolled', 'patients and for patients who are not subsequently enrolled will be maintained at the study', 'site. For adolescents (i.e., patients who are 12-17 years of age), an Informed Assent Form', 'will be completed instead. Parents or caregivers of adolescents will also complete an', 'Informed Consent Form.', 'The enrollment form will be completed after informed consent and/or assent is obtained. All', 'screening evaluations must be completed and reviewed to confirm that patients meet all', 'eligibility criteria before enrollment. The investigator will maintain a screening log to record', 'details of all patients screened and to confirm eligibility or record reasons for screening', 'failure, as applicable.', '4.5.2', 'Medical History and Demographic Data', 'Medical history includes hemophilia-related history, clinically significant diseases,', 'procedures (including prior surgeries), use of alcohol and drugs of abuse within the past year,', 'and medication allergies. In particular, sites should record whether the patient has any', 'history of prior ITI, anaphylaxis, or known thrombophilia. It should also include all medication', 'taken in the 4 weeks prior to screening (including prescription drugs, over-the-counter drugs,', 'and herbal/homeopathic remedies and therapies).', 'Emicizumab - F. Hoffmann-La Roche Ltd', '116 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}